ELOX
ELOXX PHARMACT (ELOX)
NASDAQ
$17.83-$0.62 (-3.39%)
Price as of Aug 04, 2026 8:09 AM EDT
  • $63.4M
    Market Cap
  • 1,677,172.73%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2022
12/31/2021
12/31/2020
Income Statement
Total Operating Revenue
0
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cost of Revenue
6.4M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
-6.4M
N/A
0
N/A
0
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-3.1M
-87.12%
-23.7M
-47.93%
-45.6M
+212.33%
-14.6M
N/A
Depreciation and Amortization Expense
0
-100.00%
77,000
-32.46%
114,000
+67.65%
68,000
N/A
Total Operating Expenses
6.4M
-81.30%
34.4M
-47.86%
66.0M
+97.33%
33.5M
N/A
Operating Profit
-6.4M
-81.30%
-34.4M
-47.86%
-66.0M
+97.33%
-33.5M
N/A
Interest Income
33,000
-87.96%
274,000
+3,325.00%
8,000
-97.63%
337,000
N/A
Interest Expense
-895,000
-54.08%
-1.9M
+54.81%
-1.3M
-10.65%
-1.4M
N/A
Interest Income and Expense and Net
-862,000
-48.54%
-1.7M
+33.89%
-1.3M
+16.70%
-1.1M
N/A
Total Nonoperating Income and Expense
443,000
+126.91%
-1.6M
+132.16%
-709,000
-36.81%
-1.1M
N/A
Income before Taxes
-6.4M
-81.30%
-34.4M
-47.86%
-66.0M
+90.93%
-34.6M
N/A
Income Taxes
0
N/A
0
N/A
0
N/A
0
N/A
Extraordinary Items
0
N/A
0
N/A
0
N/A
0
N/A
Net Income
-6.0M
-83.38%
-36.1M
-45.95%
-66.7M
+92.98%
-34.6M
N/A
Net Income from Continuing Operations Applicable to Common
-6.0M
-83.38%
-36.1M
-45.95%
-66.7M
+92.98%
-34.6M
N/A
Basic EPS and Net Income
-0.49
-97.06%
-16.65
+1,652.63%
-0.95
+10.47%
-0.86
N/A
Diluted EPS and Net Income
-0.49
-97.06%
-16.65
+1,652.63%
-0.95
+10.47%
-0.86
N/A
Basic Weighted Average Shares
12.3M
+469.98%
2.2M
-96.90%
70.0M
+74.36%
40.1M
N/A
Diluted Weighted Average Shares
12.3M
+469.98%
2.2M
-96.90%
70.0M
+74.36%
40.1M
N/A
Balance Sheet
Cash and Cash Equivalents
4.8M
-75.09%
19.2M
-54.56%
42.3M
+71.35%
24.7M
N/A
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
33.8M
N/A
Cash and Cash Equivalents and Short-Term Investments
4.8M
-75.09%
19.2M
-54.56%
42.3M
-27.69%
58.5M
N/A
Total Current Assets
5.3M
-73.82%
20.1M
-53.71%
43.5M
+67.92%
25.9M
N/A
Accumulated Depreciation
0
-100.00%
180,000
+5.26%
171,000
-45.37%
313,000
N/A
Property and Plant and Equipment and Net
0
-100.00%
169,000
-21.76%
216,000
+62.41%
133,000
N/A
Total Long-Term Assets
0
-100.00%
169,000
+463.33%
30,000
0.00%
30,000
N/A
Total Assets
5.3M
-75.05%
21.1M
-53.20%
45.1M
+70.48%
26.5M
N/A
Income Taxes Payable
N/A
N/A
12.5M
+236.69%
3.7M
+341.64%
843,000
N/A
Total Short-Term Debt
1.0M
-74.87%
4.0M
-24.03%
5.2M
0.00%
5.2M
N/A
Total Current Liabilities
17.2M
-25.61%
23.1M
+131.95%
10.0M
+1.19%
9.8M
N/A
Total Long-Term Debt
0
-100.00%
8.6M
-28.67%
12.0M
+88.14%
6.4M
N/A
Total Long-Term Liabilities
0
-100.00%
8.7M
-32.09%
12.8M
+99.72%
6.4M
N/A
Total Liabilities
17.2M
-45.96%
31.8M
+39.67%
22.8M
+40.06%
16.2M
N/A
Retained Earnings
-300.6M
+9.55%
-274.4M
+15.13%
-238.3M
+38.89%
-171.6M
N/A
Total Stockholders Equity
-11.9M
+11.70%
-10.7M
-147.62%
22.4M
+118.81%
10.2M
N/A
Total Shares Outstanding
4.8M
+121.12%
2.2M
-97.50%
86.6M
+115.78%
40.2M
N/A
Cash Flow
Cash from Operating Activities
-6.3M
-80.13%
-31.8M
-9.02%
-35.0M
+24.27%
-28.2M
N/A
Capital Expenditures
N/A
N/A
66,000
-25.84%
89,000
+122.50%
40,000
N/A
Cash from Investing Activities
1,000
+101.52%
-66,000
-103.21%
2.1M
-93.92%
33.8M
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
11.0M
+24.84%
8.8M
-82.65%
50.8M
+1,577.25%
-3.4M
N/A
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
N/A
N/A
-108.86%
-41.58%
-186.35%
+130.19%
-80.95%
N/A
Return on Equity
N/A
N/A
-615.23%
+50.35%
-409.19%
+174.81%
-148.90%
N/A
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
N/A
N/A
0.87
-80.04%
4.37
+65.95%
2.63
N/A
Cash Ratio
N/A
N/A
0.83
-80.41%
4.25
+69.33%
2.51
N/A
Debt-to-Equity Ratio
N/A
N/A
-1.18
-252.74%
0.77
-32.18%
1.14
N/A
Debt-to-Assets Ratio
N/A
N/A
0.59
+55.45%
0.38
-12.97%
0.44
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow